☆
Watchlist
Log in
Sign-up
Argenica Therapeutics Ltd (agn) Logo

Argenica Therapeutics Ltd (AGN)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

AGN Chart

Snapshot

AGN's Principal Activity is the research and development of a neuroprotective therapeutic drug.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) +148.55%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,635 of 2,413
Sector Rank 145 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies NYR / AZV / EX1
EPS -$0.029
DPS $0.00
Book Value Per Share $0.09

Broker Consensus

AGN is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Argenica Therapeutics Limited (AGN) is into research and development of a neuroprotective therapeutic drug. The Company is developing novel neuroprotective therapeutics to reduce brain damage after stroke.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Nedlands WA 6009
Website www.argenica.com.au
Registry Link Market Services
Auditor RSM Australia Partners
Date Listed 11 Jun 2021

Upcoming Calendar (Forecasted)

Date Event
26/08/2022 Report (Prelim)
26/08/2022 Report (Annual)
21/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Liz Dallimore Chief Executive Officer,Managing Director Apr 2022

Dr Liz Dallimore

Chief Executive Officer,Managing Director

Dr Dallimore has over 20 years' experience across Australia and the UK with focus on research & development, innovation and commercialisation. Prior to joining Argenica Therapeutics, Dr Dallimore was the Director of the WA Data Science Innovation Hub, tasked with working across WA businesses to establish innovative data science projects. Dr Dallimore has also held senior roles in management consulting across Australia, most recently as KPMG's National Director of Research Engagement and Commercialization. Prior to this she held senior roles with Ernst & Young and PricewaterhouseCoopers. Dr Dallimore is a co-founder of medical device company Inspiring Holdings, sits on the AusBiotech WA Committee and is a non-executive Director of NERA, a Federal Government Growth Centre. She has worked as a neuroscientist at the Australian Neuromuscular Research Institute (now Perron Institute).
Mr Terrence (Terry) Charles Budge Non-Executive Director Jan 2021

Mr Terrence (Terry) Charles Budge

Non-Executive Director

Mr Budge has experience in senior management and board roles. A long term banker he spent 25 years with National Australia Bank in senior executive roles before serving as Managing Director of Bankwest from 1997 to 2004. Since then he has had many non-executive director roles including Chancellor of Murdoch University from 2006 to 2013. Terry is currently a director or Tiller Rides. He is the Chair of Risk Committee.
Ms Elizabeth (Liddy) McCall Non-Executive Director Dec 2020

Ms Elizabeth (Liddy) McCall

Non-Executive Director

Ms McCall is co-founder of 3 biotechnology companies successfully achieving 3 FDA drug registrations and 1 FDA/CE Mark medical device approval. She is an inventor on patents granted in major jurisdictions translating novel G-protein coupled pharmacology into a therapeutic drug treatment currently in Phase 2 clinical trials. Liddy cofounded IIF venture capital fund, Yuuwa Capital LP, which is responsible for a portfolio of 6 companies commercializing biotechnology and IT innovation. Liddy has over 25 years of experience in senior Board and management roles including Adalta Ltd, iCeutica Inc group, Dimerix Bioscience Pty Ltd and iCetana Pty Ltd. Liddy was an Associate Director in the Corporate Advisory Group of Macquarie Bank and prior to that worked as a lawyer with a leading Australian law firm. Liddy is a non-executive director of the not-for profit Ear Science Institute Australia and also of Agworld Pty Ltd, Nexgen Plants Pty Ltd and The Tailor Made Spirits Company Limited. She is a member of Audit & Risk Committee.
Dr Samantha (Sam) South Executive Director Mar 2020

Dr Samantha (Sam) South

Executive Director

Dr South is currently the Senior Commercialisation Officer (Life Sciences) in the Research Development & Innovation office at The University of Western Australia (UWA) and has over 12 years' experience in technology transfer in medtech / biotech sector, at The University of Queensland (UQ), Queensland University of Technology and UWA. Sam has background in medical research at Weill Medical College at Cornell University (NY), UQ and The Garvan Institute in CNS research. She was also the Preclinical Manager at TetraQ, a preclinical contract organisation, specialising in central nervous system animal models. Sam was the UWA Director on UWA spin-out companies MiReven Pty Ltd, Eridan Technologies Pty Ltd and OncoRes Medical Pty Ltd and is currently a Director of Rage Biotech Pty Ltd. Sam is also WA Ausbiotech Committee Chair, part of the Ausmedtech National Advisory Group and the SBE Life Sciences Council.
Mr Geoffrey (Geoff) Richard Pocock Non-Executive Chairman,Non-Executive Director Nov 2019

Mr Geoffrey (Geoff) Richard Pocock

Non-Executive Chairman,Non-Executive Director

Mr Pocock has over 20 years experience across the commercialisation process. Geoff's experience has covered technical roles, executive management as well as significant corporate finance and strategy roles with a number of technology commercialisation ventures. Geoff is the Principal of Polaris Consulting (WA) Pty Ltd, a specialist boutique commercialisation strategy and corporate advisory business based in Western Australia. He is a member of Risk Committee.
Ms Emma Waldon Chief Financial Officer,Company Secretary N/A

Director Transactions

AGN directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
25/02/22 Terrence (Terry) Budge Buy +32,520 $0.639 $20,786 On-market trade

Director Interests

The current holdings of AGN directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Liz Dallimore 04/04/2022 N/A N/A 2,500,000 N/A
Terrence (Terry) Budge 25/02/2022 N/A 487,520 500,000 N/A
Samantha (Sam) South 30/06/2021 N/A 2,000,000 1,000,000 N/A
Geoffrey (Geoff) Pocock 30/06/2021 N/A 4,377,000 500,000 N/A
Elizabeth (Liddy) McCall 30/06/2021 N/A 125,000 500,000 N/A

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Aug 25, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Oofy Prosser Pty Ltd <Drones Family A/C> 4,377,000 5.98%
University Of Western Australia 3,953,000 5.40%
Perron Institute For Neurological And Translational Science Ltd 3,550,000 4.85%
Shane Michael Colley <Fiery King Investment A/C> 2,000,000 2.73%
Arredo Pty Ltd 1,550,000 2.12%
Shane Hoehock Wee <Wee Family A/C> 1,544,000 2.11%
Litis Super Pty Ltd <Jde Litis Super Fund> 1,500,000 2.05%
Xcel Capital Pty Ltd 1,462,500 2.00%
Bruno Philip Meloni <Bruno Meloni Family A/C> 1,277,000 1.75%
Ga Skylight Berhad 1,250,000 1.71%
Ms Helen Margaret Sewell 1,225,000 1.67%
Mr Neville William Knuckey & Mrs Jacqueline Joy Knuckey <The Knuckey Family A/C> 1,072,000 1.47%
Busso Holdings Pty Ltd <Bew A/C> 1,025,000 1.40%
Pentek Holdings Pty Ltd <The J Litis Investment No.2 A/C> 785,000 1.07%
Hugh James Pilgrim <The Hjp Family A/C> 734,500 1.00%
Mr Paul Henri Veron & Mrs Julie Anne Veron <Dead Knick S/F A/C> 725,000 0.99%
Kdjama Co Pty Ltd <Blacker Services A/C> 655,750 0.90%
Quantamatics Pty Ltd 573,000 0.78%
Ms Chunyan Niu 500,000 0.68%
Mr Luke Daniel Ferguson 500,000 0.68%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 0 0 56 462 121 639

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
University of Western Australia 25/08/2021 3,953,000 5.40
Geoffrey Pocock 25/08/2021 4,377,000 5.98

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.20 30 June
AGN Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.